A Consensus-based Guideline Defining Clinical Target Volume for Primary Disease in External Beam Radiotherapy for Intact Uterine Cervical Cancer

Takafumi Toita1,*, Tatsuya Ohno2, Yuko Kaneyasu3, Tomoyasu Kato4, Takashi Uno5, Kazuo Hatano6, Yoshiki Norihisa7, Takahiro Kasamatsu4, Takeshi Kodaira8, Ryoichi Yoshimura9,10, Satoshi Ishikura11 and Masahiro Hiraoka7 for the JCOG Radiation Therapy Study Group

1Department of Radiology, Graduate School of Medical Science, University of the Ryukyus, Okinawa, 2Gunma University Heavy Ion Medical Center, Gunma University, Maebashi, 3Department of Radiation Oncology, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, 4Division of Gynecology, National Cancer Center Hospital, Tokyo, 5Department of Radiology, Graduate School of Medicine, Chiba University, 6Division of Radiation Oncology, Chiba Cancer Center, Chiba, 7Department of Radiation Oncology and Image-applied Therapy, Kyoto University Graduate School of Medicine, Kyoto, 8Department of Radiation Oncology, Aichi Cancer Center, Nagoya, 9Department of Radiology, Tokyo Medical and Dental University, 10Department of Radiation Oncology, National Cancer Center Hospital, Tokyo, and 11Department of Radiology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

*For reprints and all correspondence: Takafumi Toita, Department of Radiology, Graduate School of Medical Science, University of the Ryukyus, 207 Uehara, Nishihara-cho, Okinawa 903-0215, Japan.
E-mail: b983255@med.u-ryukyu.ac.jp

Received April 25, 2011; accepted June 9, 2011

Objective: To develop a consensus-based guideline to define clinical target volume for primary disease (clinical target volume primary) in external beam radiotherapy for intact uterine cervical cancer.

Methods: The working subgroup of the JCOG Radiation Therapy Study Group began developing a guideline for primary clinical target volume in November 2009. The group consisted of 10 radiation oncologists and 2 gynecologic oncologists. The process started with comparing the contouring on computed tomographic images of actual cervical cancer cases among the members. This was followed by a comprehensive literature review that included primary research articles and textbooks as well as information on surgical procedures. Extensive discussion occurred in face-to-face meetings (three occasions) and frequent e-mail communications until a consensus was reached.

Results: The working subgroup reached a consensus on the definition for the clinical target volume primary. The clinical target volume primary consists of the gross tumor volume, uterine cervix, uterine corpus, parametrium, vagina and ovaries. Definitions for these component structures were determined. Anatomical boundaries in all directions were defined for the parametrium. Examples delineating these boundaries were prepared for the posterior border of the parametrium for various clinical situations (i.e. central tumor bulk, degree of parametrial involvement).

Conclusions: A consensus-based guideline defining the clinical target volume primary was developed for external beam radiotherapy for intact uterine cervical cancer. This guideline will serve as a template for radiotherapy protocols in future clinical trials. It may also be used in actual clinical practice in the setting of highly precise external beam radiotherapy, including intensity-modulated radiotherapy.

Key words: cervical cancer – radiation therapy – clinical target volume – contouring
INTRODUCTION

Standard radiotherapy for cervical cancer patients consists of external beam whole pelvic radiotherapy (EBRT) and intracavitary brachytherapy (1). Recently, treatment planning for both modalities has been shifting away from conventional two-dimensional planning to volume-based three-dimensional (3D) planning (2,3). Three-dimensional planning should achieve appropriate target coverage within sufficient doses and effective sparing of organs at risk (OARs). Intensity-modulated radiation therapy (IMRT) is the most promising 3D EBRT method, and its use has been increasing in actual clinical practice in the USA (4) and other countries. Several investigators reported promising treatment results in terms of reduced toxicity for patients with uterine cervical cancer (5–7). In Japan, IMRT has been covered by the public insurance system since April 2010 for all cancer patients. Therefore, as is now the case for other solid malignancies, the use of IMRT should be promoted for cervical cancer patients. To correctly deliver IMRT, an accurate and reproducible contouring of the clinical target volume (CTV) is primarily important and essential. There is, however, a degree of uncertainty in the delineation of the CTV (8). To achieve consistent CTV delineations, which minimize unexpected variation, consensus guidelines have been published for the pelvic lymph node CTV (9–11). A working subgroup for developing a consensus-based guideline on the CTV for cervical cancer was organized within the Radiation Therapy Study Group (RTSG) of the Japan Clinical Oncology Group (JCOG) in July 2008. The subgroup has already published a guideline on pelvic node CTV (12). More recently, the Radiation Therapy Oncology Group (RTOG) in the USA published guidelines regarding primary tumor CTV (CTV primary) for intact uterine cervical cancer (13). We have also conducted a study to establish a CTV primary guideline to perform appropriate contouring of the CTV primary in actual clinical practice as well as in the setting of clinical trials with IMRT. This paper describes the process used to develop the guideline, as well as examples of CTV delineation schemes.

RESULTS

COMPONENTS FOR THE CTV PRIMARY

The CTV primary consists of the gross tumor volume of the primary tumor (GTV primary), uterine cervix, uterine corpus, parametrium, vagina and ovaries.

DEFINITIONS FOR EACH COMPONENT STRUCTURE OF THE CTV PRIMARY

GTV PRIMARY

The GTV primary includes gross disease visible on an MRI T2-weighted image (T2WI) and lesions detected by clinical examinations.

UTERINE CERVIX

The entire cervix, if not already included within the GTV contour, is to be contoured (13). The cranial margin is defined at the level at which the uterine arteries enter the uterus (same level of the superior border of the parametrium CTV).

UTERINE CORPUS

No CTV margin should be added to the visualized corpus on CT images, even for cases in which the tumor has significant corpus invasion. This decision was based on the fact that the majority of the uterine corpus is suspended within the pelvic cavity without surrounding the connective tissue.

PATIENTS AND METHODS

The working subgroup, which was formed to establish a consensus-based guideline on the CTV for EBRT in cervical cancer, started working on the CTV for primary lesions (CTV primary) in November 2009. In addition to the original seven members, five members consisting of three radiation oncologists and two gynecologic oncologists joined the committee. The members had three face-to-face meetings and extensive discussions via e-mail throughout the working process.
Figure 1. (a) Magnetic resonance imaging (MRI) and computed tomographic (CT) slices of a FIGO Stage IIB cervical cancer patient who demonstrated bilateral parametrial invasion with nodular fixation to the right pelvic wall on pelvic exam. Clinical information for this patient was also distributed to the nine working group members along with the CT and MRI images. (b) CT images with the primary clinical target volume (CTV) contouring drawn by the working group members, which reveal substantial contouring variations among the members. (c) The same CT image with the primary CTV contouring following the present guideline.
The broad ligaments, round ligaments and ovarian ligaments do not need to be included.

Consensus was not reached regarding feasibility of excluding some portions of the uterine corpus (e.g. fundus) from the CTV primary in selected cases (i.e. non-bulky Stage I or II cases who may be candidates for radical trachelectomy).

**PARAMETRIUM**

Adipose tissues between the cervix and pelvic wall are included as well as visible linear structures that run laterally (e.g. vessels, nerves and fibrous structures).

Overlapping between the nodal CTV and the parametrium CTV is feasible (13).

Boundary structures of the parametrium CTV for each direction are listed in Table 1.

*Figure 2.* An illustration of the anatomical components around the cervix with reference to the parametrium.

<table>
<thead>
<tr>
<th>Margin</th>
<th>Structures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cranial</td>
<td>Isthmus of uterus (=level where uterine artery drains into)</td>
</tr>
<tr>
<td>*</td>
<td>*Contouring would stop at the level where bowel loops are seen</td>
</tr>
<tr>
<td>Caudal</td>
<td>Medial boarder of levator ani (Fig. 5)</td>
</tr>
<tr>
<td>Anterior</td>
<td>Posterior boarder of bladder or posterior boarder of external iliac vessels</td>
</tr>
<tr>
<td>Posterior</td>
<td>Anterior part (semicircular) of mesorectal fascia</td>
</tr>
<tr>
<td>*</td>
<td>*In case with bulky central tumor or significant parametrical invasion, some modification would be considered (Figs 3 and 4)</td>
</tr>
<tr>
<td>Lateral</td>
<td>Medial edge of internal obturator muscle, piriformis muscle, coccygeus muscle and ischial ramus</td>
</tr>
</tbody>
</table>

Figure 2.

An illustration of the anatomical components around the cervix with reference to the parametrium.

Boundary structures of the parametrium CTV for each direction are listed in Table 1. Figure 2 shows a scheme of anatomical components around the cervix with reference to the parametrium. Figures 3a and 4a show a scheme and actual delineation for the posterior border of the parametrium, respectively. Some variations are prepared as determined by the central tumor bulk or parametrial involvement status for the posterior boundary of the parametrium CTV (Figs 3 and 4). The CTV margin could be increased in the posterior direction into the perirectum (Figs 3b and 4b) and/or along the uterosacral ligaments (Figs 3c and d, and 4c and d). Figure 5 shows the primary CTV contouring at the level of the levator ani.

**VAGINA**

Paravaginal tissue would be included as well as the vaginal wall. The caudal level should be individually determined based on the findings of both the MRI and clinical examinations. Arrangements of the caudal level according to the status of vaginal invasion are stated as per the RTOG guidelines (13):

- Minimal or no vaginal extension: upper half of the vagina
- Upper vaginal involvement: upper two-thirds of the vagina
- Extensive vaginal involvement: entire vagina

**OVARY**

Ovaries visible on the CT/MRI would be included.

A consensus was not reached regarding the possibility of excluding the ovaries in selected cases (i.e. non-bulky Stage I or II cases with squamous cell carcinoma).

**AN EXAMPLE OF THE CTV PRIMARY DELINEATION (FIG. 1C)**

Figure 1c shows an example of the CTV primary delineation in accordance with the definition developed (on the same slice used in the previous comparison test).

**DISCUSSION**

The working subgroup developed a consensus-based guideline for the delineation of the CTV primary for EBRT in patients with intact uterine cervical cancer. The guideline describes the anatomical components to be included in the CTV primary, as well as the definitions for each component. Examples of CTV delineation are also included.

The guideline states that the CTV primary consists of the GTV primary, uterine cervix, uterine corpus, parametrium, vagina and ovaries. This concept seems to be almost the same with surgical treatment: radical hysterectomy, which is a standard surgical procedure for invasive cervical cancer, also includes resection of these structures.

Anatomically, the uterine corpus is concealed within the broad ligament and suspended in the pelvis. This means that no surrounding connective tissues are visible around the corpus on CT or MRI. Therefore, the guideline states that no margin should be added to the visualized corpus for the CTV. We also reached a consensus that the fallopian tubes and round ligaments would not be included in the CTV, in agreement with the RTOG guidelines (13).

The most challenging issue was delineating the parametrium and defining its anatomical boundaries on CT. This difficulty was caused by the limited information of diagnostic radiology to illustrate the relationship between transverse images and the actual parametrial anatomy. In our preliminary comparison of each member’s CTV contouring,
significant variations were observed for the parametrium. Lim et al. (13) reported a similar wide range of variation among the WG members in the RTOG. The present discrepancies were resolved through reviewing the anatomical (18–20) and surgical (21) literatures. In the present work, two gynecologic oncologists participated in addition
to the radiation oncologists. They contributed valuable information regarding surgical findings, which was instrumental for developing anatomically appropriate definitions of the boundaries. We believe that the participation of surgical oncologists is essential for the design of clinically reliable CTV definitions and contouring atlases.

The anterior and lateral boundaries are virtually identical to those specified by the RTOG guidelines (13). Minor adjustments were made to the lateral definition in the present guideline. The medial edges of the piriformis and coccygeus muscles were added to the lateral boundary. The RTOG guidelines state that the caudal margin of the parametrium is the urogenital diaphragm (13). However, the term ‘urogenital diaphragm’ usually indicates the inferior surface of the pelvic diaphragm. Therefore, we consider the superior surface of the pelvic diaphragm, which corresponds to the medial edge of the levator ani, a more appropriate term for the definition.

To determine the cranial boundary of the parametrium, we also reviewed the anatomy of the uterus and surrounding structures including the parametrium. The broad ligaments are formed by the peritoneum covering the uterine body and the parametrium (18,20). Instead of using the top of the fallopian tube/broad ligament for the cranial parametrial margin, as specified in the RTOG guidelines (13), we elected to use the cranial margin of the cervix. In an anatomical view, this margin corresponds to the isthmus of the uterus (18); however, the margin is not recognized on CT images. Therefore, the junction of the uterine artery with the uterus was proposed to be the cranial margin of the cervix. This parameter must be evaluated further clinically to ascertain the degree of variability associated with this definition.

There was extensive discussion concerning the posterior boundary of the parametrium. The RTOG guidelines use the uterosacral ligament as one of the boundaries (13). The uterosacral ligaments, however, are not always identifiable on CT images. In contrast, the mesorectal fascia is visible on the CT images in most cases. Chen et al. (22) have demonstrated that 95 and 97.5% of the CT and MRI studies, respectively, show the fascia encircling the rectum and perirectal adipose tissue as either a continuous or interrupted line. They have also shown in a cadaveric space perfusion study that the perirectal space is completely separated from the pararectal space (outside the mesorectum) by the mesorectal fascia (22). Therefore, we selected the semicircular, anterior portion of the mesorectal fascia as the posterior boundary. The RTOG guidelines include an optional definition for Stage IIIB cases (13). We also include additional areas in the parametrium CTV in cases with a bulky cervical tumor or extensive parametrial involvement. Furthermore, we developed protocol variations to address specific situations.

Chao et al. (23) stressed the importance of delivering an adequate dose to the uterosacral space for patients with uterosacral space involvement. In contrast, the RTOG guidelines recommend that the entire mesorectal space be included for patients with Stage IIIB or higher disease. We consider this to be excessive. Kato et al. (24) reported clinical outcomes for locally advanced cervical cancer patients (Stage IIB–IVA) treated with carbon ion radiotherapy. Although the posterior part of the mesorectum was not included within the CTVs, favorable local control was reported in their series (24). These results appear to support our opinion. Careful evaluation is warranted to determine whether the entire mesorectal space should be included in the CTV for patients with massive parametrial involvement, and additional discussion is still required to achieve a consensus.

Another challenge in the development of the guideline is the subdefinition of the CTV primary according to the disease status of each patient. Three-dimensional EBRT, notably IMRT, has the ability to precisely exclude structures not intended to be irradiated. There are at least two potential areas for individualization of the CTV primary in uterine cervical cancer. The first is to permit the exclusion of the ovaries. If the ovaries were excluded from the CTV primary, the planning target volume (PTV) would be smaller. The small PTV may result in lower doses and volumes delivered to the surrounding OARs. This option is feasible as several surgical studies have demonstrated that patients with early-stage cervical squamous cell cancer rarely have ovarian metastases (25,26). The second issue pertains to whether a portion of the uterine corpus may be excluded from the CTV primary. Uterine corpus exclusion may also achieve a significant decrease in the doses to the surrounding OARs. As mentioned in the previous RTOG guidelines (13), excluding a portion of the corpus would be an option for selected cases when sufficient data are available regarding the incidence and exact location of uterine recurrence after conservative surgical procedures (e.g. radical trachelectomy) (27).

Although we were not able to reach a consensus on these issues, the discussion continues. For these situations, subdivision of the CTV based on risk estimation of disease (i.e. high-, intermediate- and low-risk CTV) may be considered. The CTV primary definitions on IGBT may serve as a reference for this concept (14,15).

Although the CTV delineation for 3D EBRT planning is performed primarily based on CT/MRI findings, some small or superficial lesions may only be detected by a clinical
examination. These small/superficial lesions should also be included in the GTV. This has been addressed in the present guideline. Generally, the CTV delineation is performed on CT images. It is, however, sometimes difficult to accurately contour the CTV due to low soft tissue resolution of CT. The working subgroup recommends the use of MRI T2WI as a reference. Even with MRI, it is sometimes difficult to perform CTV contouring in thin women who have little adipose tissue in the pelvis. Solving this problem remains a challenge.

In conclusion, we propose that the present consensus-based guideline be used as a reference to perform appropriate contouring of the CTV primary in actual clinical practice as well as in the setting of clinical trials with IMRT for intact cervical cancer patients. The use of the present guideline in combination with the previously published guideline for the node (12) will minimize variation in the CTV contouring process. Additional discussion is still required to achieve a consensus regarding how much individualization will be permissible within the guideline. To perform appropriate IMRT, as well as accurate CTV contouring, consensus on the delineation of the OARs is important. Management of organ movement and tumor shrinkage over the treatment course represent additional challenges (28). Further substantial discussions are warranted to define the PTV margins for each CTV primary substructure. The working group needs to continue to develop additional consensus-based guidelines for the precise delivery of IMRT for patients with intact uterine cervical cancer.

Acknowledgements

The authors thank all of the gynecologic oncologists of the JCOG Gynecologic Cancer Study Group (GCSG), Dr Yoshinori Ito and Dr Shin Fujita for their advice and expertise.

Funding

This study was supported in part by the Grant-in-Aid for Cancer Research (20S-5) and Clinical Cancer Research (10103757) from the Ministry of Health, Labor and Welfare, Japan, and the Japan Society for the Promotion of Sciences (no. 21591614).

Conflict of interest statement

None declared.

References


**Appendix**

Other contributors of the presented work: Kazuhisa Furutani (Aichi Cancer Center, Nagoya), Naoya Murakami (National Cancer Center, Tokyo), Keiko Murofushi (Cancer Institute Hospital, Tokyo), Shin-iti Noda (Gunma University, Maebashi), Jun Itami (National Cancer Center, Tokyo), Goro Kasuya, and Takuro Ariga (University of the Ryukyus, Okinawa).